CRNX Crinetics
- 48.630
- -1.910-3.78%
- 48.630
- 0.0000.00%
Crinetics News
Crinetics Pharmaceuticals Is Maintained at Outperform by Baird
Crinetics Pharmaceuticals Is Maintained at Outperform by Baird
Crinetics Pharmaceuticals Price Target Raised to $62.00/Share From $52.00 by Baird
Crinetics Pharmaceuticals Price Target Raised to $62.00/Share From $52.00 by Baird
Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.
Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.
Cantor Fitzgerald Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $75
Cantor Fitzgerald analyst Joshua Schimmer maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $65 to $75.According to TipRanks data, the analyst has a success rate of 5
Baird Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $62
Baird analyst Brian Skorney maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $52 to $62.According to TipRanks data, the analyst has a success rate of 41.7% and a tot
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $60 to $80
On May 23, major Wall Street analysts update their ratings for $Crinetics(CRNX.US)$, with price targets ranging from $60 to $80.Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and adj
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals with a Buy and maintains $60 price target.
Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating
Crinetics Pharmaceuticals (CRNX) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $47 to $97.
Crinetics Pharmaceuticals Inc: Baird raises price target from $52 to $62
Crinetics Pharmaceuticals Inc: Baird raises price target from $52 to $62
Express News | Crinetics Pharmaceuticals Inc : Baird Raises Target Price to $62 From $52
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Promising Atumelnant Data for CAH
Crinetics Pharma Gains After Early Release of Study Data
Market-Moving News for May 22nd
CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late-breaking abstracts.BZFD: 69% | BuzzFeed shares are trading higher after
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Crinetics(CRNX.US) Officer Sells US$148.29K in Common Stock
$Crinetics(CRNX.US)$ Officer Betz Stephen F. sold 3,000 shares of common stock on May 10, 2024 at an average price of $49.43 for a total value of $148.29K.Source: Announcement What is statement of cha
18 Analysts Have This To Say About Crinetics Pharmaceuticals
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.The table below provides a con
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $65 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals with a Overweight and maintains $65 price target.
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)
Analysis
Price Target
No Data
